Robert K. Bright

Robert K. Bright is a Professor and Graduate Program Advisor in the Department of Immunology and Molecular Microbiology at Texas Tech University Health Sciences Center School of Medicine. His research focuses on cancer immunology and vaccinology, particularly in developing vaccines targeting tumor-associated antigens like Tumor Protein D52 (TPD52) for multiple cancer types.

Education:

• BS in Bacteriology, University of Idaho (1987)
• PhD in Microbiology and Immunology, University of Texas Health Sciences Center San Antonio (1994)
• IRTA Fellow, National Cancer Institute/NIH (1996)

Dr. Bright's research program centers on three interconnected pillars: (1) discovery/validation of novel tumor antigens using genomics and proteomics, (2) innovative vaccine design strategies, and (3) elucidating mechanisms of immune suppression—particularly CD4+/CD8+ regulatory T cells—that undermine vaccine efficacy. His lab identified TPD52 as a critical oncoprotein overexpressed across prostate, pancreatic, and melanoma cancers, though vaccine responses face regulatory T cell barriers.

Publication analysis reveals consistent emphasis on TPD52 as a translational vaccine target, with recent work (2022-2023) demonstrating how regulatory T cells modulate CD8+ responses to self-antigens. His studies bridge fundamental tumor immunology with clinical vaccine development, addressing key challenges in breaking immune tolerance to cancer.

Scientific Awards:

• Innovative Mind in Prostate Cancer Research (DOD, 2011)
• Armand J. Guarino Award for Academic Excellence (UT Health Sciences Center)
• NIH Fellows Award for Research Excellence
• Research Scholars Award (American Cancer Society)
• Outstanding Teacher and Student Advocate Award (2006)

Dr. Bright has served on national grant review panels for ACS, DOD, NASA, and NIH while mentoring 20+ graduate students now in academia, medicine, and industry. His research is continuously funded by NCI/NIH, ACS, and DOD Prostate Cancer Research Program. He leads an active laboratory investigating TPD52-based therapies and immune regulation mechanisms within the Department of Immunology and Molecular Microbiology.